Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 755 participants.
Also called NCT04518306
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 755 participants
- Sponsor
- George Medicines PTY Limited
- Registry
-
NCT04518306
-
- Other papers using this trial's data
- Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared With Placebo for Initial Treatment of Hypertension
- Long-Term Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination for the Treatment of Hypertension
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Nigeria, Sri Lanka, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT04518306. Randomized; quadruple masking; primary purpose treatment. Start 2021-06-14 (actual); primary completion 2023-09-19 (actual). Results posted on 2025-06-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension
- Acronym
- GMRx2_PCT
- Condition
- Hypertension
- Intervention (Drug)
- Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg
- Intervention (Drug)
- Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- George Medicines PTY Limited
Record details
- Record id
cardio:ct-nct04518306- Content hash
57e7b2c20b8be7cc21d261b1fb5c580d764a020e6cc21f5387faa22ccb39168a